Determining Prognostic Immune Markers in Patients With Ovarian Cancer

Recruiting now

Conditions studied: Epithelial Ovarian Cancer

In brief

The IMPRoVE study is a prospective, non-interventional, explorative cohort study to determine prognostic immune markers in patients with epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer (EOC).

Key facts

Study ID

NCT03862677

Run by

Leiden University Medical Center

People needed

300

Starts

2020-08-15

Expected to finish

2027-01-31

Last updated by the study team

2026-02-13

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Patients with (suspicion of) primary or recurrent EOC with an indication for surgery, chemotherapy and/or immunotherapy.
• Age ≥18 years.
• WHO performance status 0-2.
• Accessible for treatment and follow-up.
• Written informed consent.

You may not qualify if…

• Other active malignancy in past 5 years prior to entry into the study, except for treated non-melanoma skin cancer.
• Any known severe infection like HIV, hepatitis A, B and C.
• Receiving immune suppressive treatment.
• Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.

Where it is running

• Leiden University Medical Center — Leiden, Netherlands (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.